• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Organ function support in patients with coronavirus disease 2019: Tongji experience.2019 冠状病毒病患者的器官功能支持:同济经验。
Front Med. 2020 Apr;14(2):232-248. doi: 10.1007/s11684-020-0774-9. Epub 2020 May 14.
2
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.扩充脐带间充质干细胞(UC-MSCs)作为治疗危重症 COVID-19 患者的一种治疗策略:同情用药的理由。
Pain Physician. 2020 Mar;23(2):E71-E83.
3
Surviving 2019 novel coronavirus pneumonia: A successful critical case report.成功救治 2019 新型冠状病毒肺炎 1 例危重症患者的经验分享
Heart Lung. 2020 Nov-Dec;49(6):692-695. doi: 10.1016/j.hrtlng.2020.08.009. Epub 2020 Aug 20.
4
Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality.新型冠状病毒病 2019(COVID-19)的呼吸状况:降低死亡率的新型治疗策略的重要考虑因素。
Med Hypotheses. 2020 Jul;140:109760. doi: 10.1016/j.mehy.2020.109760. Epub 2020 Apr 22.
5
Pathophysiology and treatment strategies for COVID-19.COVID-19 的病理生理学和治疗策略。
J Transl Med. 2020 Sep 15;18(1):353. doi: 10.1186/s12967-020-02520-8.
6
COVID-19 challenge for modern medicine.现代医学面临的 COVID-19 挑战。
Cardiol J. 2020;27(2):175-183. doi: 10.5603/CJ.a2020.0055. Epub 2020 Apr 14.
7
Treatment considerations for coronavirus (COVID-19).冠状病毒(COVID-19)的治疗考量
Hosp Pract (1995). 2020 Aug;48(3):119-120. doi: 10.1080/21548331.2020.1754618. Epub 2020 Apr 13.
8
Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.对于严重新型冠状病毒病患者的皮质类固醇治疗。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8194-8201. doi: 10.26355/eurrev_202008_22508.
9
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
10
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.新型冠状病毒(SARS-CoV-2)爆发的前 75 天:最新进展、预防和治疗。
Int J Environ Res Public Health. 2020 Mar 30;17(7):2323. doi: 10.3390/ijerph17072323.

引用本文的文献

1
Thyroid Dysfunction among the Patients with Critical COVID-19.重症新型冠状病毒肺炎患者的甲状腺功能障碍
Infect Dis Clin Microbiol. 2022 Dec 21;4(4):229-235. doi: 10.36519/idcm.2022.175. eCollection 2022 Dec.
2
Study of thyroid function among COVID-19-affected and non-affected people during pre and post-vaccination.COVID-19 感染者与未感染者接种疫苗前后甲状腺功能研究。
BMC Endocr Disord. 2022 Dec 9;22(1):309. doi: 10.1186/s12902-022-01187-0.
3
Assessment of thyroid function of newly diagnosed SARS-CoV-2 infected patients in Nigeria.评估尼日利亚新诊断的 SARS-CoV-2 感染患者的甲状腺功能。
Pan Afr Med J. 2021 Sep 2;40:9. doi: 10.11604/pamj.2021.40.9.26358. eCollection 2021.
4
Liver injury in COVID-19: Known and unknown.新型冠状病毒肺炎中的肝损伤:已知与未知
World J Clin Cases. 2021 Jul 6;9(19):4980-4989. doi: 10.12998/wjcc.v9.i19.4980.
5
Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.COVID-19 相关急性呼吸窘迫综合征和肺外多器官功能障碍患者炎症细胞因子风暴中的特定细胞因子。
Virol J. 2021 Jun 4;18(1):117. doi: 10.1186/s12985-021-01588-y.
6
Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China.优化管理以降低新型冠状病毒肺炎死亡率:来自中国一家重症和危重症定点医院的经验
Front Med (Lausanne). 2021 Mar 10;8:582764. doi: 10.3389/fmed.2021.582764. eCollection 2021.
7
Thyroid Function Abnormalities in COVID-19 Patients.新型冠状病毒肺炎患者甲状腺功能异常。
Front Endocrinol (Lausanne). 2021 Feb 19;11:623792. doi: 10.3389/fendo.2020.623792. eCollection 2020.
8
Myocardial Injury at Early Stage and Its Association With the Risk of Death in COVID-19 Patients: A Hospital-Based Retrospective Cohort Study.新型冠状病毒肺炎患者早期心肌损伤及其与死亡风险的关系:一项基于医院的回顾性队列研究
Front Cardiovasc Med. 2020 Oct 30;7:590688. doi: 10.3389/fcvm.2020.590688. eCollection 2020.
9
Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19.国际临床试验注册平台中关于治疗新型冠状病毒肺炎抗病毒药物的临床试验:研究设计特征与药理机制
Drug Des Devel Ther. 2020 Sep 18;14:3803-3813. doi: 10.2147/DDDT.S272442. eCollection 2020.
10
COVID-19 and Thyroid: Progress and Prospects.COVID-19 与甲状腺:进展与展望。
Int J Environ Res Public Health. 2020 Sep 11;17(18):6630. doi: 10.3390/ijerph17186630.

本文引用的文献

1
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.中性粒细胞与淋巴细胞比值可预测 2019 冠状病毒病重症患者的早期病情。
J Transl Med. 2020 May 20;18(1):206. doi: 10.1186/s12967-020-02374-0.
2
[Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019 (revised edition)].《新型冠状病毒肺炎重型、危重型病例诊疗中国专家共识(修订版)》
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):269-274. doi: 10.3760/cma.j.cn121430-20200218-00188.
3
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病(COVID-19)疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
4
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
5
[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].《2019新型冠状病毒肺炎患者使用糖皮质激素的专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. doi: 10.3760/cma.j.issn.1001-0939.2020.03.008.
6
[Conventional respiratory support therapy for Severe Acute Respiratory Infections (SARI): Clinical indications and nosocomial infection prevention and control].[严重急性呼吸道感染(SARI)的常规呼吸支持治疗:临床指征及医院感染预防与控制]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E015. doi: 10.3760/cma.j.issn.1001-0939.2020.0015.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
9
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
10
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

2019 冠状病毒病患者的器官功能支持:同济经验。

Organ function support in patients with coronavirus disease 2019: Tongji experience.

机构信息

Department of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Department of Nephrology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

出版信息

Front Med. 2020 Apr;14(2):232-248. doi: 10.1007/s11684-020-0774-9. Epub 2020 May 14.

DOI:10.1007/s11684-020-0774-9
PMID:32405974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7220847/
Abstract

Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.

摘要

新型冠状病毒肺炎(COVID-19)是一种高传染性疾病,严重威胁人类健康。COVID-19 可引起多器官功能障碍,如呼吸和循环衰竭、肝肾功能损伤、弥散性血管内凝血、血栓栓塞等,甚至死亡。世界卫生组织报告称,重型 COVID-19 的死亡率超过 50%。目前,全球重型病例数量迅速增加,但感染患者的治疗经验仍有限。鉴于缺乏特效抗病毒药物,多器官功能支持治疗对 COVID-19 患者非常重要。为提高重型和危重型 COVID-19 患者的治愈率,降低死亡率,本文总结了中国武汉同济医院光谷院区重型和危重型 COVID-19 患者的器官功能支持治疗经验。本文系统总结了重型和危重型 COVID-19 患者呼吸、循环、肾、肝、血液等多器官和系统功能支持治疗的流程,为全球 COVID-19 的最佳治疗提供了临床参考和新策略。